TT 232

TT-232 (CAP-232), a somatostatin derivative, is a peptide SSTR1/SSTR4 agonist. TT-232 inhibits cancer cell proliferation and induces apoptosis. TT-232 is also a broad-spectrum anti-inflammatory and analgesic agent[1][2][4].

Research Areas >> Cancer

Signaling Pathways >> GPCR/G Protein >> Somatostatin Receptor

Research Areas >> Inflammation/Immunology

SSTR1

SSTR4

TT-232 (10 μg/mL, 48 h) induces apoptosis in human colon (HT-29 and SW620), pancreatic (818), leukemia (K-562), melanoma (WM 938/B, M-1 and EP) and lymphoma (HT-58) tumor cell lines[1]. TT-232 (20-30 μg/mL, 24 h) shows antiproliferative effect on various human tumor cell lines[2]. Cell Viability Assay[2] Cell Line: MCF7, PC-3, P818, K-562, 4-1ST, ect. Concentration: 20-30 μg/mL Incubation Time: 24 h Result: Inhibited cell proliferation by 87%, 90%, 98%, 95%, respectively.

TT-232 (15-750 μg/kg/day, twice a day) inhibits tumor growth in mice transplanted with Colon 26 cell[2]. TT-232 (0.6 or 15 μg/kg s.c or i.p.) shows antitumor effect on P-388 rodent lymphocytic leukemia tumor mice[3]. TT-232 (7.5-20 μg/kg, i.v.) inhibits Carrageenin-induced paw oedema in rats[4]. Animal Model: Mice transplanted with Colon 26 cell [2]. Dosage: 15, 150, 750 μg/kg/day Administration: Intraperitoneal injection (i.p.) Result: Reached 70% tumor inhibition at 750 μg/kg.